Traws Pharma, Inc. Stock Price, News & Analysis

Onconova Therapeutics, focused on developing cancer treatments, will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-16, 2022. A corporate overview by Dr. Steven Fruchtman will be available on-demand from September 12, 2022. Viewers can access the presentation here. Onconova is also conducting Phase 1 studies for its lead product, narazaciclib, and rigosertib in combination with nivolumab.

Onconova Therapeutics (NASDAQ: ONTX) reported its financial results for Q2 2022, revealing a net loss of $4.0 million, equating to $0.19 per share. Cash reserves stood at $46.5 million, sufficient for at least 18 months of operations. The company is advancing its Phase 1 trials for narazaciclib in the US and China, with encouraging safety data. Additionally, rigosertib's various investigator-sponsored trials are progressing, including a Phase 2 trial set to begin in 2022. Management expressed confidence in their clinical pipeline's potential to address unmet medical needs.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) will release its second quarter 2022 financial results on August 11, 2022. Following the results announcement, management will host a conference call and webcast at 4:30 p.m. ET to discuss financial performance and updates on clinical pipeline programs. Investors can join the call or access it via the company's website. Onconova focuses on developing targeted anti-cancer agents, with ongoing Phase 1 studies for its multi-kinase inhibitor, narazaciclib, in the U.S. and China, along with an investigator-sponsored study for rigosertib.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced key leadership promotions on June 13, 2022. Mark Guerin has been named Chief Operating Officer and continues as Chief Financial Officer, while Dr. Adar Makovski Silverstein becomes Senior Director and Head of Corporate Development. These promotions aim to leverage their expertise as the company progresses with its cancer treatment developments. Additionally, Avi Oler, Senior VP, will leave Onconova on June 17, 2022, for another opportunity. Onconova's pipeline includes clinical studies for its products narazaciclib and rigosertib.

Onconova Therapeutics announced promising preclinical data for its multi-kinase inhibitor narazaciclib, presented at the ASCO Annual Meeting. The findings suggest narazaciclib exhibits a differentiated inhibitory profile compared to approved CDK4/6 inhibitors, indicating potential safety and efficacy advantages. Specifically, narazaciclib showed stronger affinity for CDK4/cyclin D1 and reduced tolerability issues linked to GSK3β inhibition. CEO Steven M. Fruchtman emphasized the need for novel agents to overcome limitations of existing therapies, with plans to establish a recommended Phase 2 dose by year-end.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) reported its Q1 2022 financial results, showing a net loss of $4.1 million or $0.20 per share, compared to a loss of $4.7 million or $0.32 per share in Q1 2021. As of March 31, 2022, cash and equivalents totaled $50.8 million, sufficient to fund operations for at least 18 months. Ongoing Phase 1 trials for narazaciclib and rigosertib are progressing, with narazaciclib's recommended Phase 2 dose anticipated later this year. Financial performance remains stable amidst active clinical trials.

Onconova Therapeutics (NASDAQ: ONTX) announced that it will release its Q1 2022 financial results on May 11, 2022. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on pipeline programs. The company's proprietary multi-kinase inhibitor, narazaciclib, is undergoing Phase 1 trials, while rigosertib is being evaluated in a Phase 1/2a study for patients with KRAS+ non-small cell lung cancer. For details, visit www.onconova.com.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced that an abstract regarding its drug narazaciclib has been accepted for publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, titled Narazaciclib’s kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models, will be published on May 26, 2022, at 5:00 p.m. ET. Onconova is focused on developing innovative anti-cancer therapies and is currently conducting Phase 1 trials for narazaciclib in the U.S. and China.

Onconova Therapeutics (NASDAQ: ONTX) announced that Dr. Adar Makovski Silverstein will present on the narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022. Additionally, Dr. Steven Fruchtman will co-chair a pre-conference workshop on March 29, 2022, aimed at advancing kinase inhibitor development. The summit, held in Boston, will gather over 60 drug developers and feature various presentations. Onconova's narazaciclib is currently undergoing Phase 1 trials in the U.S. and China, targeting cancer treatments.